ajay gautam

8/10/2019 Ajay Gautam

1/30

Ajay Gautam

BioPharma LatAm

November 2014

Mexico

Biomedical Innovation in Emerging Markets


2/30

Mumbai to Shanghai, via NY, Mexico and Dubai

2 IMED Biotech Unit | Scientific Partnering & Alliances

20121998

2006

2009
http://www.google.com/url?sa=t&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&ved=0CAQQjRw&url=http://www.sxc.hu/photo/1182746&ei=Z4_oUuOoE--E2wXDt4DQDQ&usg=AFQjCNGKgTwgmavL1WLbv0IZPufJZXcXFwhttp://www.google.com/url?sa=t&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&ved=0CAQQjRw&url=http://www.sxc.hu/photo/1182746&ei=Z4_oUuOoE--E2wXDt4DQDQ&usg=AFQjCNGKgTwgmavL1WLbv0IZPufJZXcXFwhttp://www.canstockphoto.com/file_view.php?id=0252778http://www.canstockphoto.com/file_view.php?id=0252778http://www.canstockphoto.com/file_view.php?id=0267252http://www.canstockphoto.com/file_view.php?id=0267252http://pktlib.ta.astrazeneca.net/index.jsp?id=090082f181c1161e&action=view&latest=truehttp://pktlib.ta.astrazeneca.net/index.jsp?id=090082f181c1161e&action=view&latest=truehttp://www.canstockphoto.com/file_view.php?id=0267251http://www.canstockphoto.com/file_view.php?id=0267251


3/30

AstraZeneca is a global business, strong in

Emerging Markets


50,000employees

Approx. $4bninvested in R&D annually

Research across3 continents

Sales in over

100 countries

$25.7bn sales2013, Full Year Results

Manufacturing in16 countries #2In China

Emerging Markets

$5.4bn sales2013, Full Year Results


4/30

We are accelerating our focus on building a

competitive pipeline in our 3 core therapy areas

Content

Cardio-Metabolism

Core TAs

Oncology

Biologics

Respiratory, Inflammation,

Autoimmune

Small Molecules ImmunotherapiesProtein

engineering

We push the boundaries of science to deliver life-changing medicines



5/30

We have increased our proximity to bioscience

clusters and co-located at 3 strategic sites


Proximity to NIH,Johns Hopkins

New site in Cambridge,

close proximity to University of

Cambridge and world class UK

bioscience community

Connections to Karolinska

Institute & Medicon Valley

Gaithersburg MlndalCambridge

Leverage historical strength

Respiratory and CV/Met

Co-locate around

biologics/specialty care

Co-locate R&D in world-

class science cluster


6/30

Topics

Looking forward

AZ fostering innovation in emerging markets

Innovation in emerging markets

A few case studies

IMED Biotech Unit | Scientific Partnering & Alliances6


7/30

7

Emerging markets innovation has improved in

recent years

Private & government funding for R&D- China: 8x increased funding in 5 yrs- Russia: Skolkovo, Rusnano, RVC, etc.- Brazil: BNDES, state funding, VCs

Increasedfunding

Expandedtalent pool

Large number of science PhDs Overseas returnees Better growth opportunities

StrongerIP

IP improvements for drugs Increasing patents from EM companies /

academics

Improvedcapabilities

Bio-med bases, certified clinical sites

Strong academic institutions Publications in high impact journals

IMED Biotech Unit | Scientific Partnering & Alliances


8/30

8

but unique challenges remain in spite of

progress


Traditional focus on generics Shift philosophy to innovationInnovationculture

Ecosystems like Silicon Valley,

Boston, Cambridge, UK non-existent or at very early stages

Innovationecosystem

Need to build expertise inBiology & Translational Science

Scientificexpertise

Long lead times, cash flow needs VCs/Capital marketsBusiness model

Depth and breadth of talentneeds to be built

Talent pool


9/30

9

Emerging markets represent a diverse innovation

landscape


Gautam, A and Yang, S. 13, 646-647 (2014)


10/30

10

Biomedical funding in emerging markets is

increasing



11/30

11

Multi-facet aspects need to come together for

building R&D ecosystems


Innovation

IP


12/30

12

R&D ecosystems are still evolving


# of publication University rankings # of PhD # of patents # of clinical trials

China

Israel

Korea

Singapore

Russia

IndiaBrazil

Turkey

Mexico

S Africa

Poland

China

Israel

Korea

Singapore

Brazil

IndiaRussia

Turkey

Mexico

S Africa

Poland

China

India

Russia

Brazil

S Africa

Mexico

IsraelKorea

Singapore

Poland

Turkey

China

Korea

Brazil

Russia

India

Israel

S Africa

TurkeyMexico

Singapore

Poland

China

Korea

Israel

Brazil

Poland

India

Russia

TurkeyS Africa

Mexico

Singapore

High

Moderate

Low


13/30

Topics

Looking forward



A few case studies



14/30

14

Zhangjiang Hi-Tech Park, Shanghai: A leading R&D

hub


1992

Today


15/30

15

Israel is a leading innovation cluster


Office of

ChiefScientist

Early stage

funding
http://www.google.com/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&docid=YufopGIKBAntQM&tbnid=I18cfuQBqqJwgM:&ved=0CAUQjRw&url=http://www.audiotech.com/trends-magazine/the-unfolding-economic-miracle-in-israel/&ei=f3BiUp6vO8fb4AOX74DIDg&bvm=bv.55139894,d.eWU&psig=AFQjCNEeoxryC0ZAQ3zDqsIeRcHVhN8-sg&ust=1382269408473001http://www.google.com/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&docid=YufopGIKBAntQM&tbnid=I18cfuQBqqJwgM:&ved=0CAUQjRw&url=http://www.audiotech.com/trends-magazine/the-unfolding-economic-miracle-in-israel/&ei=f3BiUp6vO8fb4AOX74DIDg&bvm=bv.55139894,d.eWU&psig=AFQjCNEeoxryC0ZAQ3zDqsIeRcHVhN8-sg&ust=1382269408473001


16/30

16

Korea: Building strength in translational sciences


Korea Drug Development Fund (KDDF)


17/30

17

Singapore transitioned to an innovation hub


Strong government support, FDIs Leading academic research Large talent pool Venture funding


18/30

Topics

Looking forward



A few case studies



19/30

19

AZ fostering innovation in Emerging Markets


Russia

ChinaIsrael

Korea

Taiwan
http://www.canstockphoto.com/file_view.php?id=3836312http://www.canstockphoto.com/file_view.php?id=3836312http://www.sxc.hu/pic/m/b/bo/boooyaka/1134388_israel_flag_button_.jpghttp://www.sxc.hu/pic/m/b/bo/boooyaka/1134388_israel_flag_button_.jpghttp://pktlib.ta.astrazeneca.net/index.jsp?id=090082f181d548fe&action=view&latest=truehttp://pktlib.ta.astrazeneca.net/index.jsp?id=090082f181d548fe&action=view&latest=truehttp://www.hadassah.org.il/Englishhttp://www.hadassah.org.il/Englishhttp://www.canstockphoto.com/file_view.php?id=0252778http://www.canstockphoto.com/file_view.php?id=0252778


20/30

20

Leading personalized cancer research with Petrov

Institute in Russia


N. N. Petrov

Institute of Oncology

1st of its kind research collaboration in Russia

Better understand disease mutations in Russian patients

Petrov is oldest and largest oncology center in Russia

One of largest archival tumor samples in Europe

1 Million+ samples, from over 270,000 patients


21/30

21

Cardiac regeneration research with SIBS in China


Research at Shanghai Institute of Biological Sciences (SIBS)

in partnership with AstraZeneca colleagues in Sweden

Understand how newly formed coronary vessels first

develop

Recent publication in Science


22/30

22

Translational oncology research with KHIDI in

Korea


Pre-clinical and translational oncology projects

4 projects per year for 3 years, initiated from March 2014

KHIDI to coordinate solicitation of proposals from Korealocal researchers


23/30

23

Open innovation with NRPB in Taiwan


Open innovation initiative at AZ

Team up with NRPB in Taiwan to explore new indications and

unmet medical needs with academic researchers

Joint efforts to evaluate proposals from academics and funding

provided from NRPB for R&D

20 compounds provided for drug repurposing


24/30

Accessible through an Open Innovation Website

http://openinnovation.astrazeneca.com



25/30

Pharmacology ToolboxCompounds with optimised pharmacological properties are available for preclinical research to explore

novel disease biology and advance scientific knowledge

Target InnovationDo you have an innovative target idea for a drug discovery project? We may be able to help you

validate your idea, by providing access to our compound library

Clinical Compound BankPatient-ready compounds with evidence of human target coverage and manageable tolerability are

being offered for novel clinical and translational research

Open Innovation offerings across all stages of

research



26/30

New Molecule ProfilingSophisticated cheminformatics and screening technologies are offered to explore the properties and

therapeutic innovation potential of novel compounds

Suggestion BoxDo you have an idea, technology, or suggestion that fits outside of the above mentioned collaboration

offerings?

R&D ChallengesTo expand our problem solving ecosystem, we are sharing key R&D hurdles and looking to collaborate

with and reward those who bring innovative solutions

Open Innovation offerings across all stages of

research



27/30

Topics

Looking forward



A few case studies



28/30

28

Predicting the future

One may underestimate the long term changes


In the short term, people tend to grossly overestimate what theycan do in the long term, however, 25 years or greater Id say,

people underestimate what they can do. (1)

- Leroy Hood

Crystal ball gazing


29/30


20122000

19941987


30/30


ajay gautam

Documents